Olema Pharmaceuticals, Inc. (OLMA)

Market Cap	331.84M
Revenue (ttm)	n/a
Net Income (ttm)	-128.89M
Shares Out	68.42M
EPS (ttm)	-1.95
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	570
Open	n/a
Previous Close	4.850
Day's Range	n/a
52-Week Range	2.860 - 16.620
Beta	1.91
Analysts	Strong Buy
Price Target	24.50 (+405.16%)
Earnings Date	Aug 5, 2025

About OLMA

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. The company’s lead product candidate is palazestrant, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; OPERA-01, the pivotal Phase 3 clinical trial of palazestrant as a mono...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Nov 19, 2020
• Employees: 96
• Stock Exchange: NASDAQ
• Ticker Symbol: OLMA
• Website: https://olema.com

Analyst Summary

According to 4 analysts, the average rating for OLMA stock is "Strong Buy." The 12-month stock price target is $24.5, which is an increase of 405.16% from the latest price.

Price Target

$24.5

(405.16% upside)

Analyst Consensus: Strong Buy